LEADER 02852oas 2201093 a 450 001 9910144569503321 005 20251105213014.0 011 $a1557-8852 035 $a(DE-599)ZDB2520571-7 035 $a(OCoLC)45694108 035 $a(CONSER) 2005212454 035 $a(CKB)954925607868 035 $a(EXLCZ)99954925607868 100 $a20010110a19969999 sy a 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCancer biotherapy & radiopharmaceuticals 210 $aNew Rochelle, NY $cMary Ann Liebert, Inc 300 $aRefereed/Peer-reviewed 311 08$a1084-9785 517 3 $aCancer biotherapy and radiopharmaceuticals 606 $aCancer$xTreatment$vPeriodicals 606 $aRadiopharmaceuticals$vPeriodicals 606 $aBiological products$xTherapeutics$vPeriodicals 606 $aBiological Factors$xtherapeutic use 606 $aNeoplasms$xtherapy 606 $aRadioisotopes$xtherapeutic use 606 $aBiological Products$xtherapeutic use 606 $aCancer$xTraitement$vPe?riodiques 606 $aRadiopharmaceutiques$vPe?riodiques 606 $aCancer$xTreatment$2fast$3(OCoLC)fst00845538 606 $aRadiopharmaceuticals$2fast$3(OCoLC)fst01088327 608 $aPeriodical. 608 $aPeriodicals.$2fast 608 $aPeriodicals.$2lcgft 615 0$aCancer$xTreatment 615 0$aRadiopharmaceuticals 615 0$aBiological products$xTherapeutics 615 2$aBiological Factors$xtherapeutic use. 615 2$aNeoplasms$xtherapy 615 2$aRadioisotopes$xtherapeutic use. 615 2$aBiological Products$xtherapeutic use. 615 6$aCancer$xTraitement 615 6$aRadiopharmaceutiques 615 7$aCancer$xTreatment. 615 7$aRadiopharmaceuticals. 676 $a616 801 0$bF#A 801 1$bF#A 801 2$bOCLCQ 801 2$bOCLCS 801 2$bNSD 801 2$bOCLCQ 801 2$bMXC 801 2$bLGG 801 2$bPFM 801 2$bGBT 801 2$bOCLCQ 801 2$bFJM 801 2$bOCLCQ 801 2$bSERSO 801 2$bOCLCO 801 2$bDLC 801 2$bSERSO 801 2$bEUW 801 2$bOCLCQ 801 2$bU3W 801 2$bOCLCO 801 2$bOCLCF 801 2$bOCLCO 801 2$bMOW 801 2$bAU@ 801 2$bOCLCO 801 2$bWYU 801 2$bOCLCO 801 2$bUKMGB 801 2$bOCLCO 801 2$bOCLCA 801 2$bUHL 801 2$bOCLCQ 801 2$bOCLCO 801 2$bOCLCQ 801 2$bIOY 801 2$bOCLCL 801 2$bSFB 801 2$bSRU 801 2$bOCLCQ 906 $aJOURNAL 912 $a9910144569503321 996 $aCancer biotherapy & radiopharmaceuticals$92088307 997 $aUNINA